Dermatology Times, March 2021 (Vol. 42, No. 3)

The limited armamentarium of systemic therapies for atopic dermatitis has already been expanded with the approval of dupilumab. Forthcoming systemic therapies are expected to include a new biologic and three new Janus kinase (JAK) inhibitors.

Taking the polar opposite of a one-size-fits-all approach, clinicians now factor in a patient’s genetic profile, medical history, microbiome composition, lifestyle, and diet, among other parameters, otherwise known as precision medicine.